Compare DAKT & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAKT | CMPX |
|---|---|---|
| Founded | 1968 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 964.5M | 927.5M |
| IPO Year | 1996 | 2020 |
| Metric | DAKT | CMPX |
|---|---|---|
| Price | $19.06 | $1.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.57 |
| AVG Volume (30 Days) | 235.2K | ★ 12.2M |
| Earning Date | 03-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $608,932,000.00 | N/A |
| Revenue This Year | $12.06 | N/A |
| Revenue Next Year | $9.16 | $934.41 |
| P/E Ratio | $25.37 | ★ N/A |
| Revenue Growth | ★ 6.89 | N/A |
| 52 Week Low | $13.05 | $1.61 |
| 52 Week High | $28.27 | $6.88 |
| Indicator | DAKT | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 41.38 | 26.23 |
| Support Level | $18.99 | $1.61 |
| Resistance Level | $19.38 | $3.54 |
| Average True Range (ATR) | 0.56 | 0.15 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 7.59 | 46.05 |
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.